LXRX

$1.46+1.39%visit website

LEXICON PHARMACEUTICALS, INC.

Market Cap

$650M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.08

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

15.7

TTM to Jun 2026 · revenue

P/B

3.7

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

N/M

TTM to Jun 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	14,182	5,493	21,102	692	41,469
Cost of revenue	10	201	108	39	358
Research & development	18,757	11,315	12,756	17,443	60,271
Selling, general & administrative	7,602	8,757	9,234	9,750	35,343
Operating income	(12,187)	(14,780)	(996)	(26,540)	(54,503)
Net income	(12,769)	(15,530)	(1,043)	(31,775)	(61,117)
EPS (basic) ($)	(0.04)		0.00	(0.07)	(0.16)
EPS (diluted) ($)	(0.04)		0.00	(0.07)	(0.16)
Weighted avg. shares (basic)	363,399		400,240	437,653
Weighted avg. shares (diluted)	363,399		400,240	437,653

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

10 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 6, 2026 accepted 7:33 AM ET	2.02Earnings release	Document SEC ↗
May 7, 2026 accepted 7:31 AM ET	2.02Earnings release	Document SEC ↗
May 6, 2026 accepted 4:01 PM ET	1.01Material agreement2.03New debt obligation3.02Unregistered equity sale7.01Reg FD disclosure	Document SEC ↗
Apr 30, 2026 accepted 4:05 PM ET	1.01Material agreement3.02Unregistered equity sale5.03Bylaws / fiscal year5.07Shareholder vote	Document SEC ↗
Mar 5, 2026 accepted 7:01 AM ET	2.02Earnings release	Document SEC ↗
Feb 2, 2026 accepted 4:49 PM ET	1.01Material agreement3.02Unregistered equity sale3.03Holder rights modified5.03Bylaws / fiscal year7.01Reg FD disclosure	Document SEC ↗
Jan 29, 2026 accepted 4:37 PM ET	2.02Earnings release7.01Reg FD disclosure8.01Other events	Document SEC ↗
Nov 10, 2025 accepted 4:31 PM ET	8.01Other events	Document SEC ↗
Nov 6, 2025 accepted 4:57 PM ET	8.01Other events	Document SEC ↗
Nov 6, 2025 accepted 7:33 AM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

77%

W/W +4.8pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-02-25	2026-02-27	DEBBANE RAYMOND	Director	Purchase	2,000	$1.49	$3K	1.91M	View
2026-02-23	2026-02-25	DEBBANE RAYMOND	Director	Purchase	100.0K	$1.47	$147K	1.90M	View
2026-02-20	2026-02-23	DEBBANE RAYMOND	Director	Purchase	100.0K	$1.48	$148K	1.80M	View
2026-02-19	2026-02-23	DEBBANE RAYMOND	Director	Purchase	50.0K	$1.44	$72K	1.70M	View
2026-02-18	2026-02-18	DEBBANE RAYMOND	Director	Purchase	133.7K	$1.32	$176K	1.65M	View